Medtronic PLC vs Sibanye Stillwater Ltd — how do they compare? Medtronic PLC trades at $88.79 (market cap $112.24B), while Sibanye Stillwater Ltd trades at $10 (market cap $6.88B). The key difference: Medtronic PLC is far larger — about 16.3× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (8.17%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Sibanye Stillwater Ltd for 51 Days on average.
| MDT | SBSW | |
|---|---|---|
Market Cap | $112.24B | $6.88B |
Volume | 105,663,236 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $105.35 | $21.12 |
52-Week Low | $73.75 | $8.00 |
Typical Hold Time | 63 Days | 51 Days |
Enterprise Value | $131.58B | $7.78B |
Dividend Yield | 3.28% | 8.17% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
SBSW trades at $10.00, up 3.31% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company shows strong revenue growth to $129.68B in 2025 and improved cash flow, though net income remains negative. Analyst consensus is moderately bullish with a $14.25 price target, supported by recent institutional buying activity and positive coverage of H1 2026 results.
The outlook suggests potential upside based on valuation metrics (P/E 8.12, P/S 0.7) and projected 2026 profitability, but risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Investors should weigh the attractive valuation against operational execution challenges in the mining sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →